Amazon.com Inc vs Eli Lilly And Co — how do they compare? Amazon.com Inc trades at $267.6 (market cap $2.94T), while Eli Lilly And Co trades at $1,221 (market cap $1.08T). The key difference: Amazon.com Inc is far larger — about 2.7× Eli Lilly And Co's market cap, and Eli Lilly And Co pays a 0.57% dividend while Amazon.com Inc pays none. Which is the better fit depends on your goals.
| AMZN | LLY | |
|---|---|---|
Market Cap | $2.94T | $1.08T |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $284.02 | $1.24K |
52-Week Low | $198.79 | $639.43 |
Enterprise Value | $3.04T | $1.13T |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $268.92, down 3.3% over the past 24 hours, but maintains strong fundamental momentum with revenue growing to $716.92 billion in 2025 and net income reaching $77.67 billion. The stock shows a bullish technical setup with moving averages supporting upward momentum, while analyst sentiment remains overwhelmingly positive with 89% buy ratings and a $333.86 consensus price target representing 24% upside potential.
Amazon's outlook remains favorable with accelerating AI-driven growth in AWS and expanding profit margins, though investors face risks from intense retail competition and substantial capital expenditures. The company's dominant market position and strong cash flow generation support continued expansion, but execution on massive infrastructure investments will be critical for sustained shareholder returns.
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
Trailing returns across standard periods
Latest headlines on both assets
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →